Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Compare

2,166 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AXSM Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Axsome

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$179.77

▲(66.33%Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $179.77 with a high forecast of $210.00 and a low forecast of $148.00. The average price target represents a 66.33% change from the last price of $108.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"$72","211":"$211","106.75":"$106.8","141.5":"$141.5","176.25":"$176.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$210.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$179.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$148.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,106.75,141.5,176.25,211],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.66,115.53230769230768,123.40461538461538,131.27692307692308,139.14923076923077,147.02153846153846,154.89384615384614,162.76615384615383,170.63846153846154,178.51076923076923,186.3830769230769,194.25538461538463,202.1276923076923,{"y":210,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.66,113.20692307692308,118.75384615384615,124.30076923076923,129.8476923076923,135.39461538461538,140.94153846153847,146.48846153846154,152.03538461538463,157.5823076923077,163.1292307692308,168.67615384615385,174.22307692307692,{"y":179.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.66,110.76307692307692,113.86615384615385,116.96923076923076,120.07230769230769,123.17538461538462,126.27846153846154,129.38153846153847,132.48461538461538,135.5876923076923,138.69076923076923,141.79384615384615,144.8969230769231,{"y":148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$210.00

Average Price Target$179.77

Lowest Price Target$148.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$113

Hold

4.55%

Upside

Reiterated

06/11/25

Axsome Therapeutics' stock score is driven by robust revenue growth and strategic product launches, offset by financial instability due to high leverage and consistent losses. Positive technical indicators and strategic corporate events provide some support, but valuation challenges due to negative earnings weigh negatively on the overall score.

Graig SuvannavejhMizuho Securities

Mizuho Securities

$210

Buy

94.30%

Upside

Reiterated

06/11/25

Mizuho Securities Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/10/25

Truist Financial Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Joel BeattyRobert W. Baird

Robert W. Baird

$162→$157

Buy

45.26%

Upside

Reiterated

06/10/25

Robert W. Baird Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

David AmsellemPiper Sandler

Piper Sandler

$148

Buy

36.94%

Upside

Reiterated

06/10/25

Axsome Therapeutics (AXSM) Gets a Buy from Piper Sandler

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$180

Buy

66.54%

Upside

Reiterated

06/09/25

Positive Outlook for Axsome Therapeutics Despite Regulatory Setback, Driven by Promising Pipeline and Market Potential

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

06/09/25

Axsome Therapeutics' Growth Prospects Remain Strong Despite FDA Setback on AXS-14

Marc GoodmanLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/09/25

Axsome Therapeutics: Buy Rating Affirmed Amid Promising Pipeline Developments and Strategic Focus

Ami FadiaNeedham

Needham

$153→$150

Buy

38.79%

Upside

Reiterated

06/09/25

Axsome Therapeutics' Strategic Response to FDA Feedback Supports Buy Rating

Jay OlsonOppenheimer

Oppenheimer

$185→$183

Buy

69.32%

Upside

Reiterated

06/09/25

Oppenheimer Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Cerena ChenWells Fargo

Wells Fargo

$165

Buy

52.66%

Upside

Reiterated

06/09/25

Axsome Therapeutics: Overcoming AXS-14 Setback with Strategic Focus on AXS-05

Joseph ThomeTD Cowen

TD Cowen

$190

Buy

75.80%

Upside

Reiterated

06/09/25

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Harrow Health (HROW)

Vikram PurohitMorgan Stanley

Morgan Stanley

$190

Buy

75.80%

Upside

Reiterated

06/06/25

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), Apellis Pharmaceuticals (NASDAQ: APLS) and Bio-Rad Laboratories (NYSE: BIO)

Jason GerberryBank of America Securities

Bank of America Securities

$176

Buy

62.84%

Upside

Reiterated

05/14/25

Axsome Therapeutics (AXSM) Receives a Buy from Bank of America Securities

Yatin SunejaGuggenheim

Guggenheim

$195

Buy

80.42%

Upside

Reiterated

05/05/25

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), TG Therapeutics (NASDAQ: TGTX) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$113

Hold

4.55%

Upside

Reiterated

06/11/25

Graig SuvannavejhMizuho Securities

Mizuho Securities

$210

Buy

94.30%

Upside

Reiterated

06/11/25

Mizuho Securities Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/10/25

Truist Financial Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Joel BeattyRobert W. Baird

Robert W. Baird

$162→$157

Buy

45.26%

Upside

Reiterated

06/10/25

Robert W. Baird Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

David AmsellemPiper Sandler

Piper Sandler

$148

Buy

36.94%

Upside

Reiterated

06/10/25

Axsome Therapeutics (AXSM) Gets a Buy from Piper Sandler

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$180

Buy

66.54%

Upside

Reiterated

06/09/25

Positive Outlook for Axsome Therapeutics Despite Regulatory Setback, Driven by Promising Pipeline and Market Potential

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

06/09/25

Axsome Therapeutics' Growth Prospects Remain Strong Despite FDA Setback on AXS-14

Marc GoodmanLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/09/25

Axsome Therapeutics: Buy Rating Affirmed Amid Promising Pipeline Developments and Strategic Focus

Ami FadiaNeedham

Needham

$153→$150

Buy

38.79%

Upside

Reiterated

06/09/25

Axsome Therapeutics' Strategic Response to FDA Feedback Supports Buy Rating

Jay OlsonOppenheimer

Oppenheimer

$185→$183

Buy

69.32%

Upside

Reiterated

06/09/25

Oppenheimer Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

Cerena ChenWells Fargo

Wells Fargo

$165

Buy

52.66%

Upside

Reiterated

06/09/25

Axsome Therapeutics: Overcoming AXS-14 Setback with Strategic Focus on AXS-05

Joseph ThomeTD Cowen

TD Cowen

$190

Buy

75.80%

Upside

Reiterated

06/09/25

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Harrow Health (HROW)

Vikram PurohitMorgan Stanley

Morgan Stanley

$190

Buy

75.80%

Upside

Reiterated

06/06/25

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), Apellis Pharmaceuticals (NASDAQ: APLS) and Bio-Rad Laboratories (NYSE: BIO)

Jason GerberryBank of America Securities

Bank of America Securities

$176

Buy

62.84%

Upside

Reiterated

05/14/25

Axsome Therapeutics (AXSM) Receives a Buy from Bank of America Securities

Yatin SunejaGuggenheim

Guggenheim

$195

Buy

80.42%

Upside

Reiterated

05/05/25

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), TG Therapeutics (NASDAQ: TGTX) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

1 Month

xxx

Success Rate

14/23 ratings generated profit

Average Return

+25.18%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.87% of your transactions generating a profit, with an average return of +25.18% per trade.

3 Months

xxx

Success Rate

16/23 ratings generated profit

Average Return

+47.38%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +47.38% per trade.

1 Year

Leonid TimashevRBC Capital

Success Rate

14/16 ratings generated profit

Average Return

+26.04%

reiterated a buy rating last month

Copying Leonid Timashev's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +26.04% per trade.

2 Years

xxx

Success Rate

29/33 ratings generated profit

Average Return

+54.02%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.88% of your transactions generating a profit, with an average return of +54.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AXSM has received 54 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 179.77.

Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$1.05 with a range of -$1.67 to -$0.46. The previous quarter’s EPS was -$1.22. AXSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year AXSM has Preformed in-line its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $140.03M with a range of $135.11M to $148.10M. The previous quarter’s sales results were $121.46M. AXSM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AXSM has Preformed in-line its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 179.77.

What is AXSM’s upside potential, based on the analysts’ average price target?

Axsome Therapeutics Inc has 66.33% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AXSM a Buy, Sell or Hold?

Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is Axsome Therapeutics Inc’s price target?

The average price target for Axsome Therapeutics Inc is 179.77. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $210.00 ,the lowest forecast is $148.00. The average price target represents 66.33% Increase from the current price of $108.08.

What do analysts say about Axsome Therapeutics Inc?

Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of AXSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

AXSM Analyst Ratings

AXSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Axsome Therapeutics

AXSM Analyst Recommendation Trends

AXSM Financial Forecast

AXSM Earnings Forecast

AXSM Sales Forecast

AXSM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts